COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Biomarkers in Pulmonary Hypertension Associated to Interstitial Lung Disease

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00820729
Recruitment Status : Completed
First Posted : January 12, 2009
Last Update Posted : September 18, 2012
Information provided by (Responsible Party):
Charlotte Andersen, University of Aarhus

Brief Summary:

The presence of an abnormally increased pulmonary blood pressure worsens the prognosis of patients with interstitial pulmonary disease.

The aim of this study is to estimate the frequency of an increased blood pressure in the lungs among patient with interstitial pulmonary disease, and to evaluate the use of different biomarkers in diagnosis of the condition.

Condition or disease
Interstitial Lung Disease Pulmonary Hypertension Biomarkers

Detailed Description:

The presence of increased pulmonary blood pressure is established by echocardiography and confirmed by right heart catheterization.

The ability of NT-proBNP, vWf, troponin-t, D-dimer and exhaled NO to predict the presence of increased pressure in the pulmonary circulation is evaluated.

Layout table for study information
Study Type : Observational
Actual Enrollment : 212 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: The Prevalence of Pulmonary Hypertension and the Significance of Different Biomarkers in Chronic Interstitial Lung Disease
Study Start Date : March 2009
Actual Primary Completion Date : March 2011
Actual Study Completion Date : March 2011

Patients with interstitial pulmonary disease

Biospecimen Retention:   Samples With DNA
blood samples

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population
Out-patients with interstitial pulmonary disease.

Inclusion Criteria:

  • Interstitial pulmonary disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00820729

Layout table for location information
Department of Cardiology, Skejby sygehus
Århus N, Denmark, DK-8200
Department of Pulmonary Diseases, Århus Sygehus
Århus, Denmark, Dk-8000
Sponsors and Collaborators
University of Aarhus
Layout table for additonal information
Responsible Party: Charlotte Andersen, MD, University of Aarhus Identifier: NCT00820729    
Other Study ID Numbers: Fibrosis-ECHO 2009
First Posted: January 12, 2009    Key Record Dates
Last Update Posted: September 18, 2012
Last Verified: September 2012
Keywords provided by Charlotte Andersen, University of Aarhus:
interstitial lung disease
pulmonary hypertension
von Willebrand factor
Exhaled NO
Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Diseases
Hypertension, Pulmonary
Lung Diseases, Interstitial
Vascular Diseases
Cardiovascular Diseases
Respiratory Tract Diseases